Any questions? How should a patient be managed who is being treated for sputum positive pulmonary tuberculosis and becomes jaundiced in the third week of chemotherapy?
Campbell
I A
IA
Sully Hospital, Cardiff, Wales.
D000995:Antitubercular Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects; D007565:Jaundice / Q000139:chemically induced*; D011718:Pyrazinamide / Q000009:adverse effects; D012293:Rifampin / Q000009:adverse effects; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin